Ignite Creation Date:
2025-12-25 @ 1:11 AM
Ignite Modification Date:
2025-12-25 @ 11:22 PM
Study NCT ID:
NCT04012593
Status:
COMPLETED
Last Update Posted:
2021-04-30
First Post:
2017-09-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Diary-based Study on the Course of Hormone-withdrawal Migraines
Sponsor:
University of Zurich
Organization:
Study Overview
Official Title:
Single Centered Diary-based Study to Identify Course and Characteristics of Hormone Withdrawal Headaches/Migraines in Users of Combined Hormonal Contraceptives
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Single centered diary-based study to identify course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives Objectives of the Research Project: to identify the course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives (CHC)
Detailed Description:
Participant recruitment is performed through advertisement placed in University Zürich (USZ) online. Advertisement in offices of neurologists and headache specialists, homepage of the Swiss headache society.
Interested women contact the investigators via email and are called back by one of the study doctors or students within 1 day from Monday-Friday. This phone call is thought to inform the women about the study in more detail and for the investigators to check eligibility. During this call the participants are informed about the study procedure and can ask any question. Here most important points are use of a CHC in a 21/7 regimen, regular (at least once on two months) withdrawal migraine/headaches, intention to continue the use of the contraceptive for 3 more months.
If the participants decide to participate, inclusion and exclusion criteria are checked. If women are applicable they receive the consent form and the study information with an envelope for return. If more questions come up the investigators are available per email and phone for answers. If a patient doesn't return the consent form the investigator will delete the personal data, which collected before. Only the year of birth will be noted in the personal data.
After consent participants receive headaches diaries (with mail /post) and a prepaid envelope (for return). Participants are also offered the option to return their diaries electronically via email to the study doctor. Furthermore participants receive in a second phone contact instructions, how to fill in the headache diary and the day of study start (first day of the next pill package).
Headache diaries should be returned monthly (per email or post) and are conducted for 3 pill cycles.
If complete headache diaries are not returned participants will be contacted per email after 1 week to remind the participants. If this email is not being answered within another week a phone contact will take place to identify potential reasons for noncompliance or withdrawal of consent or drop out.
Observation period 3 pill cycles : 3 times 28 days
Outcomes of the Research Project:
* Daily number of headaches and migraine in each day of the observation cycle.and during the Hormone-free interval (HFI)
* First day of migraine in the pill-free interval
* Start of migraine in relation to withdrawal bleeding
* Start of and number of prolonged migraines \>24 hours in the pill-free interval and the phase of hormone intake.
* Pain intensity in the pill-free interval in comparison to the pill-phase
* Number of rescue medications/ migraine day during HFI and during pill intake
* efficacy of the medications (did medication stop the attack and did the attack return after maximal 8 hours)
* Within patient variability of the first migraine day in the HFI.
Statistical Methodology:
* Primary and secondary endpoints will be calculated as frequencies and percentages.
* For comparison the number of prolonged attacks during pill use and the HFI prolonged attacks per day of the observation interval are calculated and thereafter chi-square test for comparisons is used .
* Software programme is used for data analyses.
Interested women contact the investigators via email and are called back by one of the study doctors or students within 1 day from Monday-Friday. This phone call is thought to inform the women about the study in more detail and for the investigators to check eligibility. During this call the participants are informed about the study procedure and can ask any question. Here most important points are use of a CHC in a 21/7 regimen, regular (at least once on two months) withdrawal migraine/headaches, intention to continue the use of the contraceptive for 3 more months.
If the participants decide to participate, inclusion and exclusion criteria are checked. If women are applicable they receive the consent form and the study information with an envelope for return. If more questions come up the investigators are available per email and phone for answers. If a patient doesn't return the consent form the investigator will delete the personal data, which collected before. Only the year of birth will be noted in the personal data.
After consent participants receive headaches diaries (with mail /post) and a prepaid envelope (for return). Participants are also offered the option to return their diaries electronically via email to the study doctor. Furthermore participants receive in a second phone contact instructions, how to fill in the headache diary and the day of study start (first day of the next pill package).
Headache diaries should be returned monthly (per email or post) and are conducted for 3 pill cycles.
If complete headache diaries are not returned participants will be contacted per email after 1 week to remind the participants. If this email is not being answered within another week a phone contact will take place to identify potential reasons for noncompliance or withdrawal of consent or drop out.
Observation period 3 pill cycles : 3 times 28 days
Outcomes of the Research Project:
* Daily number of headaches and migraine in each day of the observation cycle.and during the Hormone-free interval (HFI)
* First day of migraine in the pill-free interval
* Start of migraine in relation to withdrawal bleeding
* Start of and number of prolonged migraines \>24 hours in the pill-free interval and the phase of hormone intake.
* Pain intensity in the pill-free interval in comparison to the pill-phase
* Number of rescue medications/ migraine day during HFI and during pill intake
* efficacy of the medications (did medication stop the attack and did the attack return after maximal 8 hours)
* Within patient variability of the first migraine day in the HFI.
Statistical Methodology:
* Primary and secondary endpoints will be calculated as frequencies and percentages.
* For comparison the number of prolonged attacks during pill use and the HFI prolonged attacks per day of the observation interval are calculated and thereafter chi-square test for comparisons is used .
* Software programme is used for data analyses.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: